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Received June 25, 2015; accepted September 7, 2015AbstractBackground: The outcomes of drug-eluting stent (DES) versus bare-metal stent (BMS) use in patients with diabetic mellitus (DM) and acute
coronary syndrome (ACS) are rarely reported in Taiwan. This study aimed to investigate the 1-year cardiovascular outcomes of DESs versus
BMSs implanted in Taiwanese patients with DM and ACS.
Methods: For this study, we collected and analyzed patient information from the database of the Taiwan ACS Full Spectrum registry regarding
characteristics and cardiovascular events in participants with DM and ACS who received implantation of either BMS (BMS group) or DES (DES
group) from October 2008 to January 2010.
Results: We found that several characteristics significantly varied between the groups. Compared with the BMS group (n ¼ 575), the DES group
(n ¼ 199) had significantly lower rates of in-hospital cardiogenic shock (1.5% vs. 4.9%, p ¼ 0.037) and acute renal failure (0.5% vs. 4.5%,
p ¼ 0.008), all-cause mortality (5.0% vs. 8.9%, p ¼ 0.048), and major adverse cardiac events (MACEs) at 1 year (11.1% vs. 18.6%, p ¼ 0.006)
with an identical target vessel revascularization (TVR) rate (6.0% vs. 7.3%, p ¼ 0.395). The BMS group had significantly higher risk-adjusted
all-cause mortality [hazard ratio (HR) ¼ 2.4, 95% confidence interval (CI) 1.0e5.7; p ¼ 0.048] and MACE (HR ¼ 2.2, 95% CI 1.2e3.9;
p ¼ 0.011) at 1 year with identical risks of TVR (HR ¼ 1.3, 95% CI 0.6e2.9; p ¼ 0.505) and nonfatal myocardial infarction (HR ¼ 1.5, 95% CI
0.5e4.4; p ¼ 0.478).
Conclusion: The results of this study support the use of DES over BMS in Taiwanese patients with DM and ACS, providing the clinical benefits
of lower rates of total mortality and MACE, and without increased TVR at 1 year in a real-world setting.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Acute coronary syndrome (ACS) is generally caused by
acute atherothrombosis, and it characteristically presents with
ST-segment elevation myocardial infarction (STEMI), non-
STEMI (NSTEMI), or unstable angina (UA). Both ACS and
diabetes mellitus (DM) are powerful independent predictors
for adverse cardiovascular events such as target lesion revas-
cularization, target vessel revascularization (TVR), major
adverse cardiac events (MACEs), or mortality after percuta-
neous coronary intervention (PCI).1e9 Studies including ran-
domized controlled trials (RCTs),10,11 observational
trials,3,8,9,12e21 and meta-analysis trials22e24 have well-
established that use of drug-eluting stents (DESs) is safe and
effective in patients with acute myocardial infarction
(AMI)3,12,13 or in patients with DM,12e21 as compared with
use of bare-metal stents (BMSs). Placement of DES primarily
benefits patients with lower repeat revascularization, but
inconsistent results have been observed concerning mortality,
myocardial infarction (MI), or MACE.3,8e24 Studies
comparing the impact of implantation of DES versus BMS on
cardiovascular outcomes in patients with both DM and ACS
are very rare,12,13 especially those in Taiwan, although DES
has been popularly used in Taiwan. This study was therefore
designed to analyze real-world data involving Taiwanese pa-
tients with DM and ACS who received either BMS or DES
implantation. Patient data were collected from the database of
the Taiwan ACS Full Spectrum (ACS FS) registry, which was
a multicenter, prospective, and observational registry study
performed to evaluate real practices in ACS management.25e27
This study aimed to describe patterns of use of BMS and DES
for Taiwanese patients with DM and ACS, and to investigate
the 1-year clinical outcome between the BMS and DES groups
in a real-world setting.
2. Methods2.1. Study designThe Taiwan ACS FS registry study was performed in
accordance with guidelines set forth in the Declaration of
Helsinki and local regulatory guidelines. The Medical Ethics
Committee (Joint Institutional Review Board Number: 08-070-
A) approved the study protocol at each participating site, and
written informed consent was obtained from all participants.
The study protocol was reviewed and allowed by the Publica-
tion Committee of the Taiwan ACS FS registry. In addition, the
authors were authorized to collect the relevant data from the
database of the registry and report the analysis. This study was
designed to analyze the data involving participants with DM
and ACS undergoing either DES or BMS implantations and to
compare 1-year clinical outcomes between the DES and BMS
groups. The registry study was a multicenter, prospective,
nonrandomized, observational study with an intention to recruit
over 3000 ACS participants and evaluate real practices in ACS
management. The names of the principal investigators who
participated in the registry study are listed in Appendix 1.2.2. Study populationParticipants were recruited from 39 participating sites,
which were distributed throughout the country and selected by
the Scientific Committee of the Taiwan Society of Cardiology
according to the annual volume of PCI performed. Approxi-
mately 50e200 consecutive ACS patients were recruited as
eligible patients in each participating site. Eligible patients
were aged 20 years or older, were hospitalized within 24 hours
after the onset of ACS symptoms, or transferred in from a
nonparticipating site with less than a 12-hour stay. Diabetic
participants were confirmed clinically according to the
guidelines and treated by diet control alone, oral hypoglyce-
mic agents, insulin, or a combination of these. Participants
with DM and ACS implanted with either DES alone or BMS
alone were categorized as the DES group and the BMS group,
respectively. Any type of BMS or DES available in the do-
mestic health care system was allowed at the interventionists'
discretion. One or more stents implanted were also permitted
in the index PCIs. The classes of DES used in the study
included sirolimus-, paclitaxel- (PES), zotarolimus-, and
everolimus-eluting stent during the registry period. Excluded
patients were those who presented with ACS secondary to
comorbidity such as trauma or bleeding, or participated in an
investigational drug study. Patients who were not diagnosed
with DM, did not undergo coronary stenting, or received
hybrid stenting with both BMS and DES were also excluded.
Physicians independently determined the treatment strategies
and made all clinical decisions. Thereafter, all participants
were followed at scheduled 3 months, 6 months, 9 months, and
12 months after discharge. Participant data with respect to
characteristics, clinical presentations, index PCI procedures,
medication prescriptions, and relevant adverse events between
groups were gathered from the case record forms. Medication
prescriptions of aspirin, clopidogrel, dual antiplatelet therapy
(DAPT) with aspirin plus clopidogrel, beta-blockers, angio-
tensin-converting enzyme inhibitors or angiotensin receptor
blockers, and statins were also compared during the 1-year
follow-up between groups.2.3. In-hospital and 1-year eventsThe in-hospital and 1-year relevant adverse events were
compared between the stent groups. Cardiovascular end points
at 1 year including mortality, nonfatal MI, nonfatal hemor-
rhagic or ischemic stroke, ischemia-driven TVR, and com-
posites of cardiovascular events such as MACE (defined as a
composite of total mortality, nonfatal MI, and TVR) were
primarily observed. In-hospital adverse events included mor-
tality, nonfatal MI, unplanned revascularization, nonfatal
hemorrhagic or ischemic stroke, cardiogenic shock, ventricu-
lar arrhythmia, and acute renal failure. A study end point was
clinically confirmed by investigators at study sites and head-
quarters according to the symptoms, electrocardiographic
findings, cardiac enzymes, and/or images. Acute renal failure
was defined as a rise (>0.5 mg/dL) in serum creatinine level
beyond the baseline value.28
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(SAS Institute Inc., Cary, NC, USA) in the analytic center. All
categorical data and rates are displayed as percentages and
numbers, and continuous data are shown as means ± standard
deviation. Baseline and outcome data were compared between
the two groups using the Chi-square test or Fisher exact test for
categorical variables, and using the analysis of variance test for
continuous variables. KaplaneMeier analysis with log-rank test
was used to detect differences in cumulative event-free survival
at 1 year between the two groups. Hazard ratios (HRs) and 95%
confidence interval (CI) were calculated from a Cox regression
model in an unadjusted or adjusted manner for other covariates.
Demographic characteristics (age, sex, and body mass index),
stent type, Killip class, hypertension, smoke, family history of
atrial fibrillation, history of heart failure and cerebrovascular
accident, history of MI, PCI, or bypass surgery, use of insulin,
and ACS type were included. Each of the aforementioned
variables was used for its univariate association with 1-year
total mortality in the Cox regression model. Covariates that
were significantly associated with 1-year mortality with a sig-
nificance level of p < 0.05 were selected for the multivariate
Cox model. Stepwise model selection with critical value of
p < 0.15 and p > 0.25 was used for variable selection and for
variable elimination. A p value less than 0.05 with two-sided
95% CI was considered statistically significant for all tests.
Analyses were conducted as time to first event without double
counting of events within analyses involving composite end
points. In the registry, patients who were lost to follow-up wereFig. 1. Participant selection flowchart. Data on 1122 eligible participants with diabe
these participants, 232 who did not receive percutaneous coronary intervention (PC
drug-eluting stent (DES) alone were excluded. The remaining 774 participants with
(n ¼ 199). CABG ¼ coronary artery bypass grafting.censored at the time of last contact, with their vital status
deemed as alive and event-free at that time.
3. Results3.1. Demographics and characteristics of the BMS and
DES groupsFrom the cohort of 3183 ACS participants enrolled between
October 2008 and January 2010, data on 1122 participants
with DM and ACS were collected. Among them, 232 partic-
ipants who did not receive PCI were excluded for analysis. In
the remaining 890 participants, 80 who did not receive coro-
nary stenting and 36 who received coronary hybrid stenting
with both BMS and DES were also excluded. Finally, 774
participants with a mean age of 64.7 ± 12.0 years who
received implantations of either BMS or DES (1 or more
stents) were ultimately enrolled as the BMS group (n ¼ 575,
74.3%) and the DES group (n ¼ 199, 25.7%), respectively
(Fig. 1). The study population included 51.3% STEMI pa-
tients, 37.0% NSTEMI patients, and 11.7% UA patients.
There were apparent demographic and characteristic vari-
ations between the stent groups. The DES group was more
likely to have a family history of vascular disease, prior PCI,
presentation as non-ST-segment elevation ACS (NSTEACS),
PCI at the left main trunk, and persistent prescriptions of
DAPT ( p < 0.05). By contrast, current smoking, presentation
as STEMI, PCI at the right coronary artery, thrombolysis in MI
0/1 blood flow, and use of intra-aortic balloon pump (IABP)
were more common in the BMS group ( p < 0.05). In addition,tes mellitus (DM) and acute coronary syndrome (ACS) were collected. Among
I) and 116 who did not receive stentings with bare-metal stent (BMS) alone or
DM and ACS were divided into the BMS group (n ¼ 575) and the DES group
Table 1
Baseline characteristics between the BMS and DES groups.
BMS (n ¼ 575) DES (n ¼ 199) p
Age (y) 64.4 ± 11.9 65.7 ± 12.6 0.203
Male, n (%) 417 (72.5) 141 (70.9) 0.651
Body mass index, (kg/m2) 25.6 ± 4.0 25.9 ± 4.0 0.345
History of, n/N (%)
Diabetic treatment
Diet control 55/555 (9.9) 26/191 (13.6) 0.156
Oral hypoglycemic agents 466/553 (84.3) 161/192 (83.9) 0.893
Use of insulin 79/575 (13.7) 33/199 (16.6) 0.326
Dyslipidemia 277/571 (48.5) 105/199 (52.8) 0.302
Hypertension 421/569 (74.0) 151/199 (75.9) 0.599
Cigarette smoker 214/567 (37.7) 53/195 (27.2) 0.008
Family history of vascular disease 89/420 (21.2) 47/147 (32.0) 0.008
Known CAD, n/N (%) 151/575 (26.3) 68/199 (34.2) 0.033
MI 55/149 (36.9) 21/66 (31.8) 0.471
PCI 101/149 (67.8) 55/67 (82.1) 0.030
Coronary artery bypass surgery 19/149 (12.8) 10/67 (14.9) 0.665
Congestive heart failure 32/575 (5.6) 12/199 (6.0) 0.807
Atrial fibrillation 15/574 (2.6) 6/199 (3.0) 0.764
Cerebrovascular accidence 74/575 (12.9) 19/199 (9.6) 0.214
Blood pressure/heart rate at ED
Systolic blood pressure (mmHg) 140.7 ± 33.6 142.8 ± 31.9 0.443
Diastolic blood pressure (mmHg) 80.9 ± 21.5 80.4 ± 20.4 0.776
Heart rate (bpm) 85.5 ± 24.1 84.8 ± 22.8 0.693
ACS types, n/N (%) <0.001
ST elevation MI 321/575 (55.8) 76/199 (38.2)
Non-ST elevation MI 200/575 (34.8) 86/199 (43.2)
Unstable angina 54/575 (9.4) 37/199 (18.6)
Killip classification, n/N (%) 0.121
I 252/476 (52.9) 93/153 (60.8)
II 98/476 (20.6) 23/153 (15.0)
III 63/476 (13.2) 24/153 (15.7)
IV 63/476 (13.2) 13/153 (8.5)
Median time to CAG (h) 4.9 25.5 <0.001
Culprit coronary artery, n/N (%)
Left main 9/575 (1.6) 9/199 (4.5) 0.017
LAD 290/575 (50.4) 103/199 (51.8) 0.747
LCX 108/575 (18.8) 43/199 (21.6) 0.386
RCA 227/575 (39.5) 55/199 (27.6) 0.003
TIMI artery flow before PCI, n/N (%) 0.005
TIMI 0/1 291/503 (57.9) 77/173 (44.5)
TIMI 2 122/503 (24.3) 49/173 (28.3)
TIMI 3 90/503 (17.9) 47/173 (27.2)
Peak cardiac enzymes (in-hospital)
CK (U/L) 917.6 ± 1546.3 839.2 ± 1246.7 0.544
CK-MB (U/L) 56.6 ± 90.9 40.7 ± 62.9 0.032
Troponin I or T (mg/L) 15.6 ± 52.5 10.0 ± 17.5 0.167
Echocardiography (in-hospital if obtained), n/N (%) 0.494
Normal 269/464 (58.0) 91/146 (62.3)
Mild 117/464 (25.2) 35/146 (24.0)
Moderate 56/464 (12.1) 17/146 (11.6)
Severe 22/464 (4.7) 3/146 (2.1)
Estimated EF (if done) 52.7 ± 12.6 54.1 ± 13.1 0.262
PCI, n/N (%)
Done within 48 h 426/569 (74.9) 123/195 (63.1) 0.002
Median time to PCI (h) 5.3 26.0 <0.001
Number of lesions treated 1.4 ± 0.7 1.6 ± 0.8 0.026
Intra-aortic balloon pump, n/N (%) 130/574 (22.7) 31/199 (15.6) 0.034
ACS ¼ acute coronary syndrome; BMS ¼ bare-metal stent; CAD ¼ coronary artery disease; CAG ¼ coronary angiogram; CK ¼ creatine kinase; CK-
MB ¼ creatine kinase-myocardial band; DES ¼ drug-eluting stent; ED ¼ emergency department; EF ¼ ejection fraction; LAD ¼ left anterior descending artery;
LCX ¼ left circumflex artery; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; TIMI ¼ thrombolysis in
myocardial infarction.
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with the DES group (5.3 hours vs. 26.0 hours, p < 0.001).
Baseline characteristics were outlined between the stent
groups as noted in Table 1.3.2. One-year cardiovascular outcomeCompared with the BMS group, the DES group appeared to
have significantly lower cumulative 1-year incidence of total
mortality (5.0% vs. 8.9%; p ¼ 0.048; Fig. 2A), but identical
incidence of nonfatal MI (3.5% vs. 3.8%; p ¼ 0.745; Fig. 2B),
TVR (6.0% vs. 7.3%; p ¼ 0.395; Fig. 2C), or nonfatal stroke
(2.5% vs. 1.6%; p ¼ 0.162; Fig. 2D) using KaplaneMeier
analysis and the log-rank test. Significant reductions with the
DES-associated treatment were shown in the cumulative 1-
year incidence of MACE (11.1% vs. 18.6%; p ¼ 0.006;
Fig. 3A) and the composite of total mortality, nonfatal MI,
TVR, and nonfatal stroke (12.6% vs. 19.8%; p ¼ 0.009;
Fig. 3B) with a decreasing trend noted in the composite of
total mortality, nonfatal MI, and nonfatal stroke (9.1% vs.
13.4%; p ¼ 0.062; Fig. 3C).3.3. In-hospital outcomeIn-hospital cardiogenic shock (4.9% vs. 1.5%; p ¼ 0.037),
use of IABP (22.7% vs. 15.6%; p ¼ 0.034), and acute renalFig. 2. One-year cardiovascular events including (A) all-cause mortality, (B) nonfat
shown between the bare-metal stent (BMS) and drug-eluting stent (DES) grou
revascularization.failure (4.5% vs. 0.5%; p ¼ 0.008) occurred more commonly
in the BMS group compared with the DES group. The other
in-hospital adverse events were equivalent between the DES
and BMS groups including total mortality (1.7% vs. 1.5%;
p ¼ 1.000), cardiac mortality (1.6% vs. 1.0%; p ¼ 0.738),
nonfatal MI (0.9% vs. 1.5%; p ¼ 0.431), unplanned revascu-
larization (0.2% vs. 1.0%; p ¼ 0.164), and nonfatal stroke
(0.5% vs. 0%; p ¼ 0.573). In-hospital adverse events are
shown in Table 2.3.4. Relative risk of cardiovascular eventsAfter adjusting for confounding variables, the BMS group
had significantly higher 1-year risk-adjusted total mortality
(HR ¼ 2.4, 95% CI 1.0e5.7, p ¼ 0.048), MACE (HR ¼ 2.2,
95% CI 1.2e3.9, p ¼ 0.011), and the composite of total
mortality, nonfatal MI, TVR, and nonfatal stroke (HR ¼ 1.9,
95% CI 1.1e3.2, p ¼ 0.026) compared with the DES group.
There were no differences in the 1-year risk-adjusted TVR
(HR ¼ 1.3, 95% CI 0.6e2.9, p ¼ 0.505), nonfatal MI
(HR ¼ 1.5, 95% CI 0.5e4.4, p ¼ 0.478), and the composite of
total mortality, nonfatal MI, and nonfatal stroke (HR ¼ 1.9,
95% CI 1.0e3.6, p ¼ 0.064). Unadjusted and adjusted risks of
cardiovascular events between the two groups at 1 year are
summarized in Table 3.al myocardial infarction, (C) target vessel revascularization, and (D) stroke are
ps using KaplaneMeier analysis with log-rank test. TVR ¼ target vessel
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differed significantly between the groups. In-hospital use of
any glycoprotein IIb/IIIa inhibitors (18.4% vs. 8.5%;
p ¼ 0.001) was more common in the BMS group. Pre-
scriptions of DAPT with aspirin plus clopidogrel dramati-
cally declined in both stent groups, especially in the BMS
group (89.0% in-hospital, 56.1% at 6 months, and 23.0% at
1 year), although our health-care system would provide
reimbursement for 9 months of DAPT in patients with ACS.
DAPT with aspirin plus clopidogrel was more commonly
prescribed in the DES group, for example at 6 months
(73.3% vs. 56.1%; p < 0.001). The prescription rates of
relevant medications during the 1-year follow-up are pre-
sented in Fig. 4.
4. Discussion
This observational study was based on data from the na-
tional ACS FS registry, and depicts the clinical outcomes of
the DES and BMS groups in 774 patients with DM and ACS.
The major findings of the study are as follows: (1) The DES
group appears to have significantly lower cumulative 1-yearFig. 3. KaplaneMeier plots illustrate 1-year cardiovascular composite events betw
(A) MACE (total mortality, nonfatal MI, or TVR), (B) the composite of total mort
MACE ¼ major adverse cardiac event; MI ¼ myocardial infarction; TVR ¼ targeincidences of MACE and total mortality as compared with
the BMS group; (2) in comparison with the DES group, the
BMS group had significant annual increases in risk-adjusted
total mortality by 140% (absolute risk increases by 3.9%)
and MACE by 120% (absolute risk increases by 7.6%); (3) for
Taiwanese patients with DM and ACS, there is no difference
in cumulative 1-year incidence of cardiac mortality, nonfatal
MI, TVR, or stroke between the two stent groups; and (4)
DAPT with aspirin and clopidogrel was underused for patients
with DM and ACS in Taiwan.
Coronary artery stenosis and cardiovascular events occur
commonly in patients with DM or ACS.1e9 DESs designed to
elute antihyperplasic drugs to retard neointimal growth have
been proven to reduce the incidence of coronary artery
restenosis, repeat revascularization,8e24 mortality,17,20 or
MACE.8,10,17,18,20,21 A large RCT enrolling 3009 AMI patients
receiving primary PCI demonstrated that the paclitaxel-eluting
stent (PES) group (n ¼ 2257) compared with the BMS group
(n ¼ 749) had lower rates of TVR at 1-year ( p ¼ 0.006) and at
an extended 3-year ( p ¼ 0.0003) follow-up.12,29,30 However,
the subanalysis of 478 diabetic patients with AMI disclosed no
differences in 1-year rates of TVR, total mortality, MI, stroke,
and stent thrombosis between the PES group (n ¼ 364) and the
BMS group (n ¼ 114).12 Those findings are compatible witheen the bare-metal stent (BMS) and drug-eluting stent (DES) groups including
ality, MI, or stroke, (C) the composite of total mortality, MI, TVR, and stroke.
t vessel revascularization.
Table 2
In-hospital and 1-year outcomes between the BMS and DES groups.
BMS (n ¼ 575) DES (n ¼ 199) p
In-hospital outcomes, n/N (%)
Total death 10/575 (1.7) 3/199 (1.5) >0.99
Cardiac 9/10 (90.0) 2/3 (66.7) 0.423
Re-MI 5/575 (0.9) 3/199 (1.5) 0.431
Unplanned revascularization 1/575 (0.2) 2/199 (1.0) 0.164
Hemorrhagic or ischemic stroke 3/575 (0.5) 0/199 (0.0) 0.573
TIMI bleeding 14/575 (2.4) 4/199 (2.0) >0.99
Cardiogenic shock 28/575 (4.9) 3/199 (1.5) 0.037
Ventricular arrhythmia 27/575 (4.7) 6/199 (3.0) 0.312
Atrial fibrillation 14/575 (2.4) 7/199 (3.5) 0.418
Acute renal failure 26/575 (4.5) 1/199 (0.5) 0.008
1-y CV outcomes, n/N, (%)
Total death 51/575 (8.9) 10/199 (5.0) 0.048
Cardiac 20/51 (39.2) 4/10 (40.0) >0.99
Re-MI 22/575 (3.8) 7/199 (3.5) 0.745
TVR 42/575 (7.3) 12/199 (6.0) 0.395
Hemorrhagic or ischemic stroke 9/575 (1.6) 5/199 (2.5) 0.168
Death/Re-MI/stroke 77/575 (13.4) 18/199 (9.1) 0.062
Death/Re-MI/TVR 107/575 (18.6) 22/199 (11.1) 0.006
Death/Re-MI/TVR/stroke 114/575 (19.8) 25/199 (12.6) 0.009
BMS ¼ bare-metal stent; CV ¼ cardiovascular; DES ¼ drug-eluting stent;
MI ¼ myocardial infarction; TIMI ¼ thrombolysis in myocardial infarction;
TVR ¼ target vessel revascularization.
Table 3
Cox regression analysis in stent types for estimating risk of 1-year cardio-
vascular outcomes.
HR
(unadjusted)
p * HR
(adjusted) a
p *
Total death 2.0
(1.0e4.0)
0.053 2.4
(1.0e5.7)
0.048
Cardiac death 1.8
(0.6e5.3)
0.283 1.8
(0.5e6.4)
0.340
MI 1.2
(0.5e2.8)
0.745 1.5
(0.5e4.4)
0.478
Hemorrhagic or ischemic stroke 0.7
(0.2e2.0)
0.450 0.4
(0.1e1.7)
0.232
TVR 1.3
(0.7e2.5)
0.397 1.3
(0.6e2.9)
0.505
Death/re-MI/TVR
(MACE)
1.9
(1.2e3.0)
0.008 2.2
(1.2e3.9)
0.011
Death/re-MI/stroke 1.6
(1.0e2.8)
0.066 1.9
(1.0e3.6)
0.064
Death/re-MI/TVR/stroke 1.8
(1.1e2.8)
0.011 1.9
(1.1e3.2)
0.026
HR ¼ hazard ratio (95% confidence interval; reference as the DES group);
MACE ¼ major adverse cardiac event; MI ¼ myocardial infarction;
TVR ¼ target vessel revascularization.
* Risk estimation of 1-year cardiovascular outcomes in the bare-metal stent
group referenced as the drug-eluting stent group using Cox regression analysis
for categorical variables and using analysis of variance test for continuous
variables.
a Cox regression analysis adjusted for the confounding factors including age,
body mass index, Killip class, hypertension, smoker, history of atrial fibril-
lation, heart failure, cerebrovascular accident, and use of insulin.
245C.-C. Lai et al. / Journal of the Chinese Medical Association 79 (2016) 239e247the present results suggesting that the clinical benefit of DES
implantation are primarily demonstrated through lower repeat
revascularization, and may be attenuated or abolished in pa-
tients with coexisting DM and ACS.12,13 One Taiwan study of
patients with ACS recently exhibited significant reductions in
TVR and cardiovascular composites in the DES group as
compared with the BMS group.27 Similarly, the present results
reinforced that any superiority of DES over BMS, particularly
in terms of declining TVR, was eliminated in a patient pop-
ulation with both DM and ACS who might have multivessel
coronary diseases and complex coronary lesions requiring
repeat revascularization. In addition, a large registry trial
selecting diabetic patients treated with at least one DES or
BMS with a median follow-up of 2.5 years showed a signifi-
cant reduction in the rate of propensity score risk-adjusted
coronary restenosis in the NSTEACS group implanted with
DES, but not in the STEMI group.13 Thus, implantation of
DES compared with BMS may have different effects on
clinical outcomes in various patient populations. The present
data showed that the DES group compared with the BMS
group, at a minimum, was not associated with increased
nonfatal MI and TVR during the 1-year follow-up.
Cardiovascular events are more prevalent in a diabetic
population than in a general population or nondiabetic pop-
ulation.4e9,21,22 Based on the registry data, patients with DM
and ACS compared with ACS patients receiving coronary
stentings (n ¼ 2322) had a higher cumulative 1-year incidence
of cardiovascular events.27 The DES group compared with the
BMS group showed a significant reduction in total mortality
by 2.4% in an ACS population, by 3.9% in a population with
both DM and ACS, and in MACE by 5.5% and 7.6%,
respectively.27 In other words, the BMS group was associatedwith greater than twofold adjusted risk for total mortality or
MACE as compared with the DES group. There is no doubt
that DM comorbidity deteriorates patient outcomes. Consis-
tent results obtained from several registry studies revealed a
mortality benefit of the DES group over the BMS group in
diabetic patients receiving PCI.17,20 Furthermore, use of DES
with a longer duration of DAPT may partially account for a
mortality benefit in high-risk patients. A couple of studies
have emphasized that the use of DAPT improves cardiovas-
cular outcomes in patients with ACS.31,32 The current guide-
lines recommend at least 1-year DAPT in patients with ACS,
regardless of whether or not a stent was actually implanted.33
A longer duration of DAPT may reduce cardiovascular events
and, conversely, early discontinuation of DAPT may increase
cardiovascular events,31,34e36 although the duration of DAPT
remains controversial.37e39
This observational study had several limitations. First, pa-
tients might have an elevated chance of selection because of
relatively low mortality rates and cardiovascular event rates in
the registry. Second, even after adjusting for confounding
factors, unmeasured confounders possibly existed. Third,
coronary lesion and stent characteristics such as vessel or stent
size, lesion or stent length, and thrombus burden were not
recorded. Fourth, angiographic follow-up was not mandatory
in the registry, and therefore, ischemia-driven events were not
optimally accurate because the events might be underreported.
Fifth, uneven prescriptions levels of DAPT might in part
contribute to outcome differences between the groups. Sixth,
rare stent thrombosis was not investigated, which could impact
Fig. 4. Prescription rates of relevant medications during the 1-year follow-up.
Prescription rates of dual antiplatelet therapy decline overtime in the two stent
groups, especially in the bare-metal stent (BMS) group. ACEI ¼ angiotensin-
converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker;
BB ¼ beta-blocker; DAPT ¼ dual antiplatelet therapy; DES ¼ drug-eluting
stent. * ¼ Significant differences in prescription rates of DAPT between the
DES and BMS groups.
246 C.-C. Lai et al. / Journal of the Chinese Medical Association 79 (2016) 239e247the number of cardiovascular events in the DES group. Lastly,
using a 1-year follow-up period might not be sufficient to fully
evaluate the safety and efficacy of DES.
In conclusions, this study supports the continued current
use of DES in patients with both DM and ACS in terms of
reduced total mortality or composite cardiovascular events at
1 year in a real world setting, without increased adverse car-
diac events.
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